ライフサイエンスコーパス: inhale

1 ater, which requires suppressing the urge to inhale.

2 cxr-knockout mice than in wild-type controls inhaling 200 ppm diacetyl, further implicating the alpha

3 icantly improved by treating recipients with inhaled 50% oxygen, in conjunction with prevascularizati

4 Conclusion Inhaled (99m)Tc-sestamibi clearance study is a repeatabl

5 n (P-gp) and assess the repeatability of the inhaled (99m)Tc-sestamibi clearance technique.

6 The clearance of inhaled (99m)Tc-sestamibi from the lungs of 13 patients

7 obliterative airway disease with systemic or inhaled administration.

8 Treatment effect of inhaled adrenaline was not modified by virus type, load

9 etermined a) the deposition and retention of inhaled Ag in the nasal cavity from nose-only exposure;

10 nt to allergically sensitize to an innocuous inhaled Ag.

11 Odorants are delivered to ORNs via the inhaled air at breathing frequencies that can vary from

12 osed to a multitude of noxious challenges in inhaled air.

13 Inhaled allergen challenges and skin tests were conducte

14 DM allergen, particularly when the amount of inhaled allergen is low, by expanding allergen-specific

15 Inhaled allergen significantly increased mDC and pDC num

16 early- and late-phase allergic responses to inhaled allergen.

17 atopic asthma (n = 13) were challenged with inhaled allergen.

18 nduced by dendritic cells (DCs) that present inhaled allergen.

19 Exposure to inhaled allergens generates T helper 2 (Th2) CD4(+) T ce

20 The effects of inhaled allergens on the expression of IL-17RB by mDCs a

21 ucial players in TH2 sensitization to common inhaled allergens that enter the body through the skin a

22 Our data support that impaired clearance of inhaled allergens triggering IL-13 production by multipl

23 ficant length of time and small enough to be inhaled and deposited throughout the respiratory tract.

24 nd regulated inflammatory responses to other inhaled and ingested environmental elements, such as all

25 E031 has greater efficacy than omalizumab on inhaled and skin allergen responses in patients with mil

26 ality, decline in FEV1, and response to both inhaled and systemic corticosteroids.

27 All exposed children received inhaled anesthetic agents, and anesthesia duration range

28 longitudinal study examining the effects of inhaled anti-inflammatory medications over a 48-month st

29 ts was surprising in light of differences in inhaled antibiotic and respiratory symptoms, suggesting

30 t 100-fold lower than the most commonly used inhaled antibiotic tobramycin.

31 Inhaled anticholinergics such as ipratropium bromide (IB

32 philic inflammation were poorly sustained by inhaled antigen alone but were augmented by inhalation o

33 Tolerance to inhaled antigen is mediated through induction of regulat

34 with rhinovirus can antagonize tolerance to inhaled antigen through combined induction of TSLP, IL-3

35 nonuclear phagocytes that potentially access inhaled antigens in human lungs.

36 cells and impaired immunologic tolerance to inhaled antigens.

37 Evidence for health effects of inhaled arsenic derives mainly from occupational studies

38 the majority of the excess deaths caused by inhaled arsenic exposure.

39 In contrast, inhaled arsenic has been consistently associated only wi

40 Allergic manifestations of inhaled Aspergillus include allergic bronchopulmonary as

41 cond [FEV1 ; FEV1 <65% vs >/=65% predicted], inhaled beclomethasone dipropionate dose [<600 vs >/=600

42 Participants received 6 weeks of inhaled beclomethasone dipropionate.

43 a can be controlled well in most patients by inhaled beta-adrenoreceptor (beta2 AR) agonists and ster

44 collagen accumulation in response to either inhaled bleomycin or inducible lung targeted TGF-beta1 o

45 The change in 6MWD after inhaled bronchodilator treatment and surgical lung volum

46 ory defect that is typically not reversed by inhaled bronchodilator.

47 roids were randomised to receive once daily, inhaled budesonide 400 mug (those aged <11 years 200 mug

48 Early treatment with inhaled budesonide/formoterol in patients at risk for ac

49 m 100 daily puffs was higher than the amount inhaled by a smoker consuming 10 conventional cigarettes

50 cles (3) that survive in the air and (4) are inhaled by a susceptible individual (5) who may become i

51 shown that microplastics may be ingested and inhaled by the shore crab Carcinus maenas, although the

52 ration of some toxins than mainstream smoke (inhaled by the smoker directly), making SHS potentially

53 RATIONALE: Heightened cough responses to inhaled capsaicin, a transient receptor potential vanill

54 jor obstacle for the clinical application of inhaled chemotherapy.

55 To enhance synaptic transmission, mice inhaled CO2 to induce an acidosis and activate acid sens

56 rved blunting of the ventilatory response to inhaled CO2Tac1-Pet1 neurons thus appear distinct from a

57 gned to initiate treatment with a once-daily inhaled combination of either 100 mug or 200 mug flutica

58 gned 2799 patients with COPD to a once-daily inhaled combination of fluticasone furoate at a dose of

59 been a general expectation that early use of inhaled corticosteroid (ICS) could change the natural hi

60 izumab and placebo groups during the 16-week inhaled corticosteroid (ICS) dose-stable phase were eval

61 pium is an effective treatment when added to inhaled corticosteroid (ICS) maintenance therapy.

62 ty (OW) is linked to worse asthma and poorer inhaled corticosteroid (ICS) response in older children

63 tion in sputum basophils following increased inhaled corticosteroid (ICS) treatment.

64 ssociation was modified by smoking status or inhaled corticosteroid (ICS) use.

65 ized data comparing triple therapy with dual inhaled corticosteroid (ICS)/long-acting beta2-agonist (

66 mproved therapeutic ratio over the benchmark inhaled corticosteroid 3 (fluticasone propionate) and pr

67 nist (LAMA), licensed as triple therapy with inhaled corticosteroid and long-acting beta-agonist (ICS

68 nical trials of patients with COPD that had: inhaled corticosteroid arms (fluticasone propionate and

69 ncy than either their monocomponents or LABA/inhaled corticosteroid combinations in patients at low a

70 sthma Control Questionnaire score, 0.76; and inhaled corticosteroid dosage, 550 mug/d.

71 s with mild to moderate asthma undergoing an inhaled corticosteroid dose reduction do not support the

72 elated (P < .05 for all) positively with the inhaled corticosteroid dose, total number of controller

73 have potential as a predictive biomarker of inhaled corticosteroid efficacy in the management of chr

74 ticle salmeterol dry powder twice daily plus inhaled corticosteroid for 1 to 2 weeks with a 1- to 2-w

75 with two long-acting bronchodilators and an inhaled corticosteroid in chronic obstructive pulmonary

76 with two long-acting bronchodilators and an inhaled corticosteroid in chronic obstructive pulmonary

77 agonist combinations are more effective than inhaled corticosteroid monotherapy in controlling diseas

78 quately controlled by at least a medium-dose inhaled corticosteroid plus a long-acting beta-agonist.

79 g with twice-daily long-acting beta2-agonist/inhaled corticosteroid salmeterol/fluticasone combinatio

80 ears to be a biomarker for responsiveness to inhaled corticosteroid therapy and may help identify pat

81 randomly assigned 294 patients to extrafine inhaled corticosteroid treatment (n=148) or placebo (n=1

82 asthma, to aeroallergen sensitization, or to inhaled corticosteroid treatment.

83 and raised sputum eosinophil counts despite inhaled corticosteroid treatment.

84 in their risk of pneumonia, irrespective of inhaled corticosteroid treatment.

85 cohort (n = 650), adjusting for smoking and inhaled corticosteroid use, and verified results in thre

86 After a run-in period to control for inhaled corticosteroid use, induced sputum was collected

87 o was complicated with COPD and treated with inhaled corticosteroid, long-acting beta2 agonist, long-

88 phils as a predictor of responsiveness to an inhaled corticosteroid/long-acting beta2-agonist combina

89 ts of stepping up patients with COPD from an inhaled corticosteroid/long-acting beta2-agonist combina

90 were randomized (1:1) to 7 (maximum 14) days inhaled corticosteroid/long-acting beta2-agonist flutica

91 izations in the previous year, and receiving inhaled corticosteroid/long-acting beta2-agonist with or

92 nists (LABAs) (n = 3174), 1 RCT of LABAs and inhaled corticosteroids (ICS) (n = 1097), 5 RCTs of the

93 BACKGROUND AND Inhaled corticosteroids (ICS) and inhaled corticosteroid

94 Low-dose inhaled corticosteroids (ICS) are highly effective for r

95 re two principal agents that can be added to inhaled corticosteroids (ICS) for patients with asthma t

96 been receiving either low- to medium-dosage inhaled corticosteroids (ICS) or low-dosage ICS plus lon

97 Inhaled corticosteroids (ICSs) are considered the most e

98 Inhaled corticosteroids (ICSs) are the preferred treatme

99 Inhaled corticosteroids (ICSs) are widely used as first-

100 dynamic assessment of the systemic effect of inhaled corticosteroids (ICSs) is often done by measurin

101 A allele among the 637 children treated with inhaled corticosteroids (ICSs) plus LABAs but not for tr

102 to obtain diagnoses and treatment), (2) use inhaled corticosteroids (ICSs) properly, and (3) underst

103 opium is efficacious as an add-on therapy to inhaled corticosteroids (ICSs) with or without other mai

104 d followed by 3 crossover periods with daily inhaled corticosteroids (ICSs), daily leukotriene recept

105 tic patients using LABA-containing products, inhaled corticosteroids (ICSs), leukotriene modifiers, s

106 rican and white subjects treated or not with inhaled corticosteroids (ICSs; ICS+ and ICS-, respective

107 (1:1) to 4 weeks of treatment with extrafine inhaled corticosteroids (QVAR 80 mug, two puffs twice pe

108 -agonists, is effective in patients for whom inhaled corticosteroids alone are insufficient.

109 ons, we analysed 214 patients (114 extrafine inhaled corticosteroids and 100 placebo).

110 in patients with uncontrolled asthma despite inhaled corticosteroids and at least one second controll

111 upport further study to test the efficacy of inhaled corticosteroids and beta agonists for prevention

112 Early treatment with inhaled corticosteroids and beta agonists may reduce pro

113 patients whose symptoms are uncontrolled by inhaled corticosteroids and long-acting beta-agonists.

114 Inhaled corticosteroids and long-acting beta2-agonist co

115 least two exacerbations while on high-dosage inhaled corticosteroids and long-acting beta2-agonists (

116 Combination therapy, including inhaled corticosteroids and long-acting beta2-agonists,

117 litation and bronchodilators with or without inhaled corticosteroids and oxygen; those randomized to

118 dentify patients most likely to benefit from inhaled corticosteroids and targeted anti-immunoglobulin

119 Inhaled corticosteroids are important in the management

120 ciated with increased risk of treatment with inhaled corticosteroids at age 7 years (adjusted odds ra

121 able asthmatics that were being treated with inhaled corticosteroids at the time of the study.

122 with good responders and poor responders to inhaled corticosteroids based on a subset of 145 white c

123 GROUND AND Inhaled corticosteroids (ICS) and inhaled corticosteroids combined with long-acting beta2-

124 the change in ACQ7 greater in the extrafine inhaled corticosteroids group than in the placebo group

125 RATIONALE: Inhaled corticosteroids have been shown to decrease exac

126 r single long-acting bronchodilators or LABA/inhaled corticosteroids in decreasing exacerbation.

127 aled nitric oxide (FeNO) and the response to inhaled corticosteroids in patients with non-specific re

128 f acute symptoms, but maintenance with daily inhaled corticosteroids is the standard of care for pers

129 pulations that are more likely to respond to inhaled corticosteroids or biologics.

130 vals in addition to standard care (high-dose inhaled corticosteroids plus >/=1 additional controller

131 receiving treatment with medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist

132 led persistent asthma on medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist

133 asthma who are receiving medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist

134 uncontrolled by medium-dosage to high-dosage inhaled corticosteroids plus long-acting beta(2)-agonist

135 ble safety profile, and hence in addition to inhaled corticosteroids plus long-acting beta2-agonist t

136 that remains uncontrolled despite high-dose inhaled corticosteroids plus other controller medication

137 e screening despite regular use of high-dose inhaled corticosteroids plus other controller medicines.

138 r more of blood leucocytes respond better to inhaled corticosteroids than do those with counts of les

139 be involved in a reduction in the ability of inhaled corticosteroids to impair control of airway infl

140 The results do not support restriction of inhaled corticosteroids to patients with symptoms on mor

141 Adherence with inhaled corticosteroids was similarly high for both inco

142 In patients not treated with inhaled corticosteroids, 40 (3.8%) patients with less th

143 lergic inflammation that was unresponsive to inhaled corticosteroids, but responsive to systemic cort

144 In patients treated with inhaled corticosteroids, events occurred in 107 (4.5%) v

145 rse asthma control, required higher doses of inhaled corticosteroids, had more severe airway hyperres

146 whereas severe disease can be refractory to inhaled corticosteroids, long-acting beta-agonists, and

147 mass index, vitamin D dosing regimen, use of inhaled corticosteroids, or end-study 25(OH)D levels; po

148 ave higher morbidity and reduced response to inhaled corticosteroids.

149 thelial cells recovered after treatment with inhaled corticosteroids.

150 evious 12 months and who were not on regular inhaled corticosteroids.

151 respiratory symptoms to predict response to inhaled corticosteroids.

152 es) and whether or not patients had received inhaled corticosteroids.

153 ounts less than 2% have a poorer response to inhaled corticosteroids.

154 may partly explain their reduced response to inhaled corticosteroids.

155 r rapid relief of symptoms, and daily use of inhaled corticosteroids.

156 ss in adult stable asthmatic patients taking inhaled corticosteroids.

157 Inhaled CPMV nanoparticles were rapidly taken up by and

158 Inhaled cryptococci must survive the host immune respons

159 f e-cigarette-type technology as a model for inhaled delivery of vaporized psychostimulants.

160 Inhaled diacetyl vapors are associated with flavorings-r

161 dy was to evaluate methods of estimating the inhaled dose of air pollution and understand variability

162 Further optimization of inhaled drug properties provided a second, equally poten

163 Inhaled environmental pollutants, most prominently from

164 Although inhaled exposure to drugs is a prevalent route of admini

165 abusers, preclinical models that incorporate inhaled exposure to psychomotor stimulants are not commo

166 This study evaluates the contribution of inhaled fluticasone and salmeterol, alone or combined, t

167 us A/X31 H3N2 and either or not treated with inhaled fluticasone propionate (FP), systemic corticoste

168 te and vilanterol); a control arm (not given inhaled fluticasone); and pre-randomisation measurements

169 failure from the run-in period of open-label inhaled fluticasone, and the treatment periods for subje

170 s from 3.8 to 4.8 V, users were predicted to inhale formaldehyde (up to 49 mg day(-1)), acrolein (up

171 Inhaled formulations of amphotericin B remain the most w

172 nism for the dysregulated immune response to inhaled fungi.

173 n regional gas distribution (R[r] = ratio of inhaled gas to total volume of a voxel when normalized f

174 ional quantitative information on changes in inhaled gas ventilation in response to therapy.

175 nce for the use of high-flow oxygen therapy, inhaled gases, and aerosols in the care of critically il

176 In a clinical trial the novel therapeutic inhaled GATA3 mRNA-specific DNAzyme attenuated early- an

177 rigins of obstructive lung diseases has made inhaled gene therapy an attractive alternative to the cu

178 couragingly, clinical trials have shown that inhaled gene therapy with various viral vectors and non-

179 w key components for successful execution of inhaled gene therapy, including gene delivery systems, p

180 understanding of the biological barriers to inhaled gene therapy.

181 er a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or a long-acting muscarinic antag

182 g the LABA salmeterol in combination with an inhaled glucocorticoid, fluticasone propionate.

183 oderate or severe exacerbations while taking inhaled glucocorticoid-based triple maintenance therapy.

184 It is unknown whether the concomitant use of inhaled glucocorticoids with LABAs mitigates those risks

185 ng beta-agonists and medium-to-high doses of inhaled glucocorticoids, those who received tezepelumab

186 ng beta-agonists and medium-to-high doses of inhaled glucocorticoids.

187 okers, 42% used bronchodilators and 23% used inhaled glucocorticoids.

188 of patients with osteosarcoma who were given inhaled granulocyte-macrophage colony-stimulating factor

189 ajor part of the adaptive immune response to inhaled HDM allergen, particularly when the amount of in

190 reventing allergic inflammatory responses to inhaled HDM allergen.

191 lammatory cytokine production in response to inhaled HDM in mice.

192 y using magnetic resonance (MR) imaging with inhaled hyperpolarized xenon 129 ((129)Xe).

193 our efforts to discover novel, highly potent inhaled inhibitors of PDE4.

194 led cross-over study assessing the effect of inhaled inorganic nitrite on peak exercise capacity, con

195 Microspheres inhaled into the gill chamber had a small but significan

196 is an opportunistic fungal pathogen that is inhaled into the lungs and can lead to life-threatening

197 The use of inhaled long-acting beta2-agonists alone is not appropri

198 the effect on acute inflammatory response to inhaled LPS challenge following gammaT treatment, focusi

199 lammation and acute neutrophilic response to inhaled LPS challenge in volunteers with asthma.

200 mucins, as well as acute airway response to inhaled LPS challenge.

201 oteins from the lungs limits the efficacy of inhaled medications.

202 Also the proportion of people using inhaled medicines or visiting a general practitioner for

203 2 demonstrated airway hyperresponsiveness to inhaled methacholine significantly greater than in WT BA

204 tivity) which function coordinately to clear inhaled microbes and other foreign particles from airway

205 or M. tuberculosis, are not only phagocytose inhaled microbes and particulate matter but are also cru

206 ing airways is the primary tissue exposed to inhaled microorganisms, allergens and pollutants.

207 Humans inhale mold conidia daily and typically experience lifel

208 People with higher OC exposure are likely inhaling more fresh OC2 and OC3, since secondary OC4 and

209 ts from a delay in innate immune response to inhaled Mycobacterium tuberculosis, leading to delayed a

210 Pregnant rats exposed to episodic inhaled nicotine via a novel lung alveolar region-target

211 n patients who received at least 24 hours of inhaled nitric oxide (inhaled nitric oxide group) and th

212 Importance: Inhaled nitric oxide (iNO) is an expensive, commonly use

213 c oxide group) and those who did not receive inhaled nitric oxide (no inhaled nitric oxide group).

214 al membrane oxygenation support (P = 0.007), inhaled nitric oxide (P = 0.045), sildenafil (P = 0.004)

215 large observational study demonstrated that inhaled nitric oxide administration in children with acu

216 Of these, 859 patients (4.3%) received inhaled nitric oxide for at least 24 hours during their

217 omes, including mortality, were worse in the inhaled nitric oxide group (inhaled nitric oxide vs no i

218 Prior to matching, patients in the inhaled nitric oxide group were younger, with more comor

219 d at least 24 hours of inhaled nitric oxide (inhaled nitric oxide group) and those who did not receiv

220 who did not receive inhaled nitric oxide (no inhaled nitric oxide group).

221 ; p < 0.001) were significantly worse in the inhaled nitric oxide group.

222 eks' PMA was similar between the placebo and inhaled nitric oxide groups (31.5% [n = 70] vs 34.9% [n

223 Placebo (nitrogen) or inhaled nitric oxide initiated at 20 ppm was decreased t

224 The use of inhaled nitric oxide is rarely indicated and both beta2

225 Inhaled nitric oxide might improve outcomes in a subset

226 To test whether administration of inhaled nitric oxide to preterm infants requiring positi

227 Conclusions and Relevance: Inhaled nitric oxide use is common but highly variable a

228 ere worse in the inhaled nitric oxide group (inhaled nitric oxide vs no inhaled nitric oxide; 25.7% v

229 Inhaled prostacyclins, similar to inhaled nitric oxide, are not recommended for routine us

230 Inhaled nitric oxide, initiated at 20 ppm on postnatal d

231 , high-frequency oscillatory ventilation, or inhaled nitric oxide.

232 229 infants (50.2% male [n = 115]) received inhaled nitric oxide.

233 tric oxide group (inhaled nitric oxide vs no inhaled nitric oxide; 25.7% vs 7.9%; p < 0.001; standard

234 Determine whether inhaled nitrite improves hemodynamics in HFpEF.

235 is warranted to evaluate chronic effects of inhaled nitrite in HFpEF.

236 Inhaled nitrite reduced resting pulmonary capillary wedg

237 Slow cumulative transport of inhaled nPM into the brain may contribute to delayed res

238 If inhaled or ingested, microplastics may accumulate and ex

239 ross cell types and can cause rapid death if inhaled or ingested.

240 creased duration of action commensurate with inhaled or topical delivery resulted in potent pan-JAK i

241 xidative stress and irritant responses to an inhaled oxidant: environmental tobacco smoke (ETS).

242 receptors or of AADC, or even an increase in inhaled oxygen, produces substantial relief from hypoxia

243 When inhaled, ozone (O3) interacts with cholesterols of airwa

244 Inhaled PA101 could be a treatment option for chronic co

245 We aimed to test the efficacy and safety of inhaled PA101 in patients with IPF and chronic cough and

246 d in health, instruct tolerance to innocuous inhaled particles while ensuring that efficient and rapi

247 PV1 and TRPA1, might sense selected forms of inhaled particulate materials in human airways, shaping

248 the primary physical airway defense against inhaled pathogens and irritants.

249 tant defense mechanism in the lung to remove inhaled pathogens and pollutants.

250 egrity, increasing systemic translocation of inhaled pathogens and small molecules.

251 provides an essential first host barrier to inhaled pathogens that can prevent pathogen invasion and

252 at cystic fibrosis airways do not respond to inhaled pathogens, thus favoring infection and inflammat

253 ind, randomized controlled trial, once-daily inhaled placebo, fluticasone furoate (FF; 100 mug), vila

254 rue to the hypothesis, this study shows that inhaled PLGA particles of sildenafil can be administered

255 h and disease and are essential for cleaning inhaled pollutants and pathogens from airways.

256 ers is not an absolute anatomical barrier to inhaled prion-infected or uninfected brain homogenate.

257 ar spaces that mediate the bulk transport of inhaled prions between cells of mice or hamsters followi

258 Inhaled prostacyclins, similar to inhaled nitric oxide,

259 sphodiesterase type-5 inhibitors and oral or inhaled prostanoids was permitted for WHO functional cla

260 us (4 mg/kg once per day) or oral respective inhaled R507 (60 mg/kg twice per day, each) was used for

261 In 6-day animals, oral and inhaled R507 more potently diminished mononuclear graft

262 Oral and inhaled R507 was significantly more effective in reducin

263 a randomized, controlled trial that compared inhaled racemic adrenaline versus saline.

264 er detected viruses modified the response to inhaled racemic adrenaline.

265 We inhale respiratory pathogens continuously, and the subse

266 The time taken to clear 50% of inhaled sestamibi (T1/2) was compared with a semiquantit

267 t to receive either intravenous midazolam or inhaled sevoflurane for 48 hours.

268 In patients with ARDS, use of inhaled sevoflurane improved oxygenation and decreased l

269 Inhaled short-acting beta2-agonists provide rapid relief

270 ll SR evidence on the efficacy and safety of inhaled short-acting bronchodilators to treat asthma and

271 DAS181, an inhaled sialidase, is undergoing clinical development fo

272 translocation, and microglial activation of inhaled silver nanoparticles in the rodent nose and brai

273 ing exercise before and after treatment with inhaled sodium nitrite (90 mg) or placebo.

274 Acute administration of inhaled sodium nitrite reduces biventricular filling pre

275 Whereas healthy people can inhale spores of A. fumigatus without developing disease

276 Pharmacogenetics of Adrenal Suppression with Inhaled Steroid Study).

277 We did a post-hoc analysis of the 3 year inhaled Steroid Treatment As Regular Therapy (START) stu

278 d nitric oxide, blood eosinophil counts, and inhaled steroid treatment did not influence cough parame

279 ptom control, despite lower dose maintenance inhaled steroids.

280 Cough responses to inhaled stimuli in patients with COPD, healthy smokers,

281 elation between the lung elimination rate of inhaled technetium 99m ((99m)Tc)-sestamibi and immunohis

282 critical to achieving global TB control, and inhaled therapies should be considered as one such strat

283 These studies raise concerns for inhaled therapies that selectively and effectively inhib

284 that may contribute to favorable effects of inhaled therapies.

285 RATIONALE: Objective adherence to inhaled therapy by patients with chronic obstructive pul

286 mdl3(Delta2-3/Delta2-3)/CC10) to simulate an inhaled therapy that effectively inhibited ORMDL3 expres

287 Notwithstanding potential neurotoxicity of inhaled titanium dioxide nanoparticles (TiO2 NPs), the t

288 tor modulators (SGRMs) was developed for the inhaled treatment of respiratory diseases.

289 The aim of this study was to assess whether inhaled treatment with a combined treatment of the corti

290 We have reported that a single inhaled treatment with a synergistic combination of Toll

291 according to the route of allergen exposure (inhaled vs food allergens).

292 diac cause were randomized to receive either inhaled xenon (40% end-tidal concentration) combined wit

293 to assess clinical outcomes associated with inhaled xenon among survivors of out-of-hospital cardiac

294 nts were randomly assigned to receive either inhaled xenon combined with hypothermia (33 degrees C) f

295 The authors previously reported that inhaled xenon combined with hypothermia attenuates brain

296 survivors of out-of-hospital cardiac arrest, inhaled xenon combined with hypothermia compared with hy

297 OHCA, in comparison with hypothermia alone, inhaled xenon combined with hypothermia suggested a less

298 tment) or to cooling in combination with 30% inhaled xenon for 24 h started immediately after randomi

299 The proposed method images the uptake of inhaled xenon gas to the extravascular brain tissue comp

300 ondary objective was to assess the effect of inhaled xenon on myocardial ischemic damage in the same